Karri A. Bauer

2.6k total citations
54 papers, 1.9k citations indexed

About

Karri A. Bauer is a scholar working on Applied Microbiology and Biotechnology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Karri A. Bauer has authored 54 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Applied Microbiology and Biotechnology, 18 papers in Infectious Diseases and 16 papers in Epidemiology. Recurrent topics in Karri A. Bauer's work include Antibiotic Use and Resistance (31 papers), Antibiotic Resistance in Bacteria (16 papers) and Bacterial Identification and Susceptibility Testing (16 papers). Karri A. Bauer is often cited by papers focused on Antibiotic Use and Resistance (31 papers), Antibiotic Resistance in Bacteria (16 papers) and Bacterial Identification and Susceptibility Testing (16 papers). Karri A. Bauer collaborates with scholars based in United States, South Africa and United Kingdom. Karri A. Bauer's co-authors include Debra A. Goff, Jessica E. West, Julie E. Mangino, Kurt Stevenson, Preeti Pancholi, Katherine K. Perez, Graeme N. Forrest, Joan‐Miquel Balada‐Llasat, Erica Reed and James M. O’Brien and has published in prestigious journals such as Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy and The Lancet Infectious Diseases.

In The Last Decade

Karri A. Bauer

52 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Karri A. Bauer United States	24	833	686	586	572	482	54	1.9k
Michael Postelnick United States	26	517 0.6×	498 0.7×	696 1.2×	486 0.8×	406 0.8×	88	2.3k
Emily L. Heil United States	28	744 0.9×	608 0.9×	646 1.1×	836 1.5×	748 1.6×	139	2.6k
Edina Avdic United States	18	753 0.9×	430 0.6×	353 0.6×	667 1.2×	447 0.9×	39	1.7k
Melinda M. Neuhauser United States	23	883 1.1×	333 0.5×	553 0.9×	896 1.6×	567 1.2×	73	2.4k
Mamoon A. Aldeyab United Kingdom	22	807 1.0×	305 0.4×	462 0.8×	472 0.8×	296 0.6×	83	1.5k
Mark Gilchrist United Kingdom	23	1.2k 1.5×	234 0.3×	750 1.3×	572 1.0×	492 1.0×	48	2.4k
Arno Müller Belgium	23	1.0k 1.2×	248 0.4×	490 0.8×	707 1.2×	418 0.9×	47	2.1k
Andrew M. Morris Canada	29	1.1k 1.3×	791 1.2×	816 1.4×	1.1k 2.0×	285 0.6×	135	3.1k
Jerod Nagel United States	20	542 0.7×	699 1.0×	536 0.9×	706 1.2×	237 0.5×	57	1.6k
Rebekah W. Moehring United States	27	680 0.8×	400 0.6×	783 1.3×	675 1.2×	244 0.5×	123	2.2k

Countries citing papers authored by Karri A. Bauer

Since Specialization

Citations

This map shows the geographic impact of Karri A. Bauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karri A. Bauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karri A. Bauer more than expected).

Fields of papers citing papers by Karri A. Bauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karri A. Bauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karri A. Bauer. The network helps show where Karri A. Bauer may publish in the future.

Co-authorship network of co-authors of Karri A. Bauer

This figure shows the co-authorship network connecting the top 25 collaborators of Karri A. Bauer. A scholar is included among the top collaborators of Karri A. Bauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karri A. Bauer. Karri A. Bauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

DeRyke, C Andrew, Mark G. Wise, Karri A. Bauer, et al.. (2025). Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018–2022 Global Surveillance. Journal of the Pediatric Infectious Diseases Society. 14(1).

Karlowsky, James A., Sibylle Lob, Karri A. Bauer, et al.. (2023). Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates—SMART United States 2019–21. JAC-Antimicrobial Resistance. 6(1). dlad152–dlad152. 11 indexed citations

Cantón, Rafael, Thomas Gottlieb, Geoffrey W. Coombs, et al.. (2023). Antimicrobial surveillance: A 20-year history of the SMART approach to addressing global antimicrobial resistance into the future. International Journal of Antimicrobial Agents. 62(6). 107014–107014. 11 indexed citations

Bauer, Karri A., Laura Puzniak, Kalvin Yu, et al.. (2023). Association of SARS-CoV-2 status and antibiotic-resistant bacteria with inadequate empiric therapy in hospitalized patients: a US multicenter cohort evaluation (July 2019 - October 2021). BMC Infectious Diseases. 23(1). 490–490. 4 indexed citations

Puzniak, Laura, et al.. (2023). A multicenter evaluation of antibacterial use in hospitalized patients through the SARS-Cov-2 pandemic waves. BMC Infectious Diseases. 23(1). 117–117. 1 indexed citations

Bauer, Karri A., Kalvin Yu, Pamela Moise, et al.. (2023). Morbidity and mortality of hospitalised patients with candidemia during the various severe acute respiratory syndrome coronavirus 2 pandemic waves: A multicentre evaluation of 248 US hospitals. Mycoses. 66(6). 483–487. 6 indexed citations

Bauer, Karri A., Laura Puzniak, Kalvin Yu, et al.. (2022). Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation. BMC Infectious Diseases. 22(1). 841–841. 13 indexed citations

Puzniak, Laura, Lyn Finelli, Kalvin Yu, et al.. (2021). A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19. BMC Infectious Diseases. 21(1). 227–227. 23 indexed citations

Bauer, Karri A., Kelly Johnson, Judith J. Stephenson, et al.. (2020). Rate of preventative vaccine use and vaccine beliefs among a commercially insured population. Vaccine. 38(45). 7087–7093. 3 indexed citations

10.

Goff, Debra A., Karri A. Bauer, Adrian Brink, et al.. (2020). International Train the Trainer antibiotic stewardship program for pharmacists: Implementation, sustainability, and outcomes. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 3(5). 869–876. 10 indexed citations

11.

Goff, Debra A., Ravina Kullar, Karri A. Bauer, & Thomas M. File. (2017). Eight Habits of Highly Effective Antimicrobial Stewardship Programs to Meet the Joint Commission Standards for Hospitals. Clinical Infectious Diseases. 64(8). 1134–1139. 50 indexed citations

12.

Bremmer, Derek N., Joan-Miquel Balada-Llasat, Debra A. Goff, & Karri A. Bauer. (2017). Ceftriaxone Etest non-susceptible methicillin susceptible Staphylococcus aureus time-kill responses. Diagnostic Microbiology and Infectious Disease. 88(2). 192–194. 1 indexed citations

13.

Bauer, Karri A., Eric Wenzler, Debra A. Goff, et al.. (2017). Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection. Anaerobe. 48. 1–6. 28 indexed citations

14.

Bauer, Karri A., Charles H. Cook, Julie E. Mangino, et al.. (2016). Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia. European Journal of Clinical Microbiology & Infectious Diseases. 35(9). 1433–1439. 22 indexed citations

15.

Wenzler, Eric, Debra A. Goff, Julie E. Mangino, et al.. (2015). Impact of rapid identification of Acinetobacter Baumannii via matrix-assisted laser desorption ionization time-of-flight mass spectrometry combined with antimicrobial stewardship in patients with pneumonia and/or bacteremia. Diagnostic Microbiology and Infectious Disease. 84(1). 63–68. 47 indexed citations

16.

Moise, Pamela, Annie Wong‐Beringer, Kenneth C. Lamp, et al.. (2015). Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation. Clinical Therapeutics. 38(1). 16–30. 50 indexed citations

17.

Goff, Debra A., et al.. (2013). A Stewardship Program’s Retrospective Evaluation of Vancomycin AUC24/MIC and Time to Microbiological Clearance in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis. Clinical Therapeutics. 35(6). 772–779. 55 indexed citations

18.

Reed, Erica, Jessica E. West, Preeti Pancholi, et al.. (2013). Improving the management of candidemia through antimicrobial stewardship interventions. Diagnostic Microbiology and Infectious Disease. 78(2). 157–161. 53 indexed citations

19.

Goff, Debra A., et al.. (2012). Is the "Low-Hanging Fruit" Worth Picking for Antimicrobial Stewardship Programs?. Clinical Infectious Diseases. 55(4). 587–592. 77 indexed citations

20.

Bazan, José A., Karri A. Bauer, Alan S. Hollister, et al.. (2010). Peramivir Pharmacokinetics in Two Critically Ill Adults with 2009 H1N1 Influenza A Concurrently Receiving Continuous Renal Replacement Therapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(10). 1016–1020. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact